NASDAQ:MRTX

MRTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Mirati Therapeutics, Inc. Is Fair to Shareholders

Retrieved on: 
Monday, October 9, 2023
Legal, Professional Services, U.S. FDA, Sale, Bristol Myers Squibb, Fraud, Contingent value rights, NSCLC, Patient, Advertising, Security (finance), Mirati

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Mirati Therapeutics, Inc. (NASDAQ: MRTX) to Bristol Myers Squibb for $58.00 per share in cash is fair to Mirati shareholders.

Key Points: 
  • Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Mirati Therapeutics, Inc. (NASDAQ: MRTX) to Bristol Myers Squibb for $58.00 per share in cash is fair to Mirati shareholders.
  • On behalf of Mirati shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.
  • Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Mirati To Present Updated Clinical Data at ESMO Congress 2023

Retrieved on: 
Wednesday, September 27, 2023
KRAS, MB, ESMO, FRCPE, Mirati Therapeutics, Oncology, NSCLC, PST, NHS Grampian, Lung cancer, Harvard Medical School, Patient, Mass, SAN, CEST, Mirati, Hospital, NHS, European Society for Medical Oncology, Pembrolizumab, Therapy, GI, Treatment, Safety, Pharmaceutical industry, Music, Royal College of Pathologists

SAN DIEGO, Sept. 27, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage research and development biotechnology company, today announced several presentations to be unveiled at the European Society of Medical Oncology Congress 2023 taking place October 20 to 24, 2023 in Madrid, Spain, including updated clinical data showcasing the feasibility and potential of the investigational combination of KRASG12C inhibitor, adagrasib with pembrolizumab in a study of treatment naïve patients with advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation.

Key Points: 
  • "Adagrasib is the first targeted KRASG12C inhibitor to show promising efficacy and early signs of durability in combination with an immune checkpoint inhibitor in the front line setting," said Alan Sandler , M.D.
  • chief medical officer, Mirati Therapeutics.
  • of Mass General Cancer Center, Harvard Medical School and Keith Kerr, MB ChB, FRCPath, FRCPE of NHS Grampian.
  • The symposium will be held on October 23 from 13:00-14:30 CEST in the Valencia Auditorium, Hall 10, IFEMA Madrid.

Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Retrieved on: 
Tuesday, September 5, 2023
Employment, Therapy, RSU, Mirati Therapeutics, SAN, Pharmaceutical industry, Life insurance, Mirati

SAN DIEGO, Sept. 5, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced that the company granted equity awards to 3 new employees with a grant date of September 1, 2023, as equity inducement awards outside of the company's 2022 Equity Incentive Plan (but under the terms of the company's Inducement Plan) and material to the employee's acceptance of employment with the company.

Key Points: 
  • SAN DIEGO, Sept. 5, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced that the company granted equity awards to 3 new employees with a grant date of September 1, 2023, as equity inducement awards outside of the company's 2022 Equity Incentive Plan (but under the terms of the company's Inducement Plan) and material to the employee's acceptance of employment with the company.
  • The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The employees received, in the aggregate, options to purchase 25,531 shares of Mirati's common stock, and in the aggregate, 15,089 restricted stock units ("RSUs").
  • The options have an exercise price of $37.75 per share, which is equal to the closing price of Mirati's common stock on September 1, 2023, (the "Grant Date").

Mirati Therapeutics to Participate at the Morgan Stanley 21st Annual Global Healthcare Conference

Retrieved on: 
Tuesday, August 29, 2023
Mirati, Webcast, Morgan, Therapy, Mirati Therapeutics, Conference, SAN, Pharmaceutical industry, Broadcasting

SAN DIEGO, Aug. 29, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, will participate at the Morgan Stanley 21st Annual Global Healthcare Conference on September 12 at 12:35 p.m. P.T.

Key Points: 
  • SAN DIEGO, Aug. 29, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, will participate at the Morgan Stanley 21st Annual Global Healthcare Conference on September 12 at 12:35 p.m. P.T.
  • Ben Hickey , chief commercial officer, and Jamie Christensen , Ph.D., chief scientific officer, will represent the company in a fireside chat at the conference.
  • Investors and the general public are invited to listen to a live webcast of the session through the "Investors and Media" section on Mirati.com .
  • A replay of the webcast will be made available following the event.

Mirati Therapeutics Announces Departure of Chief Financial Officer Laurie Stelzer

Retrieved on: 
Wednesday, August 23, 2023
Arena Pharmaceuticals, CFO, Regeneron Pharmaceuticals, Therapy, Mirati Therapeutics, Financial management, Patient, FP, SAN, Strategic planning, Pharmaceutical industry, Management, Mirati

SAN DIEGO, Aug. 23, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced that Laurie Stelzer, Chief Financial Officer, will depart the company on September 8, 2023, to pursue an external opportunity.

Key Points: 
  • SAN DIEGO, Aug. 23, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced that Laurie Stelzer, Chief Financial Officer, will depart the company on September 8, 2023, to pursue an external opportunity.
  • Aaron Ondrey, senior vice president, financial planning and analysis (FP&A), Mirati Therapeutics, will assume the role of interim CFO.
  • "On behalf of the Board and the Company, we thank Laurie for her leadership and the contributions made during her tenure," said Charles M. Baum, M.D., Ph.D., interim CEO, president and founder, Mirati Therapeutics.
  • "It has been a privilege to serve as CFO of Mirati and I am grateful for the opportunity and the experience to work alongside a team committed to positively impacting the lives of patients," said Laurie Stelzer, chief financial officer, Mirati Therapeutics.

Mirati To Present Pooled Clinical Data from Adagrasib's KRYSTAL-1 Study Demonstrating Overall Survival Results at Two-Years of Follow-Up at 2023 World Conference on Lung Cancer

Retrieved on: 
Monday, August 21, 2023
Mirati, KRAS, Lung cancer, Therapy, SGT, Mirati Therapeutics, Patient, NSCLC, Conference, SAN, Pharmaceutical industry, Birth control

SAN DIEGO, Aug. 21, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced a presentation of two-year follow-up from a pooled analysis of the Phase 1/1b Cohort and Phase 2 Cohort A for the KRYSTAL-1 study evaluating adagrasib in in patients with non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation.

Key Points: 
  • SAN DIEGO, Aug. 21, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced a presentation of two-year follow-up from a pooled analysis of the Phase 1/1b Cohort and Phase 2 Cohort A for the KRYSTAL-1 study evaluating adagrasib in in patients with non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation.
  • Findings will be presented at the 2023 World Conference on Lung Cancer during the press conference on September 10th10:35 a.m. – 10:40 a.m. SGT / September 9th7:35 p.m. – 7:40 p.m. PT and as a mini-oral presentation in the "Targeted Therapy: KRAS and Beyond" session occurring on September 10th at 4:22 p.m. SGT / 1:22 a.m. PT.

Mirati Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Retrieved on: 
Friday, August 11, 2023
Exercise, Attention, SVB Securities, File, Telephone, Mirati Therapeutics, Goldman Sachs, Sale, Prospectus, SAN, Mirati, Security (finance), Therapy

This includes the exercise in full by the underwriters of their option to purchase up to 1,618,705 additional shares of common stock.

Key Points: 
  • This includes the exercise in full by the underwriters of their option to purchase up to 1,618,705 additional shares of common stock.
  • The aggregate gross proceeds to Mirati from this offering were approximately $345.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Mirati.
  • Goldman Sachs & Co. LLC acted as the book-running manager for the proposed offering.
  • A final prospectus supplement and accompanying prospectus relating to the offering were filed with the SEC and are available on the SEC's website located at http://www.sec.gov .

Cancer Discovery Publishes Preclinical and Initial Clinical Data for MRTX1719 to Treat MTAP-Deleted Cancers through Novel Approach to MTA-Cooperative PRMT5 Inhibition

Retrieved on: 
Wednesday, August 9, 2023
Neutropenia, MTAP, Prevalence, MTA, Neoplasm, Mirati Therapeutics, Clinical trial, Cancer Discovery (journal), Cancer, Doctor of Philosophy, Lung, MD Anderson Cancer Center, MD, Patient, SAN, University, Anemia, Mesothelioma, Pulmonary toxicity, Therapy, Kinetics, Thrombocytopenia, PRMT5, Pharmaceutical industry, Vaccine, Medical imaging

SAN DIEGO, Aug. 9, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, announced today Cancer Discovery published preclinical and initial clinical data from a first-in-human Phase 1/2 clinical trial of MRTX1719, a PRMT5 / methylthioadenosine (MTA)-cooperative inhibitor evaluated in methylthioadenosine phosphorylase (MTAP) deleted cancers. These results provide preclinical and early clinical proof-of-concept for this differentiated approach and demonstrate that MRTX1719 may represent a promising targeted therapy for the ~10% of cancer patients with this biomarker. The publication can be found here.

Key Points: 
  • These results provide preclinical and early clinical proof-of-concept for this differentiated approach and demonstrate that MRTX1719 may represent a promising targeted therapy for the ~10% of cancer patients with this biomarker.
  • In preclinical studies, MRTX1719 was demonstrated to be a potent, selective inhibitor of the PRMT5/MTA complex.
  • Preclinical results showed marked anti-tumor activity of MRTX1719, including regression, across lung, pancreatic, mesothelioma, and other solid tumor models.
  • "It will be important for next-generation sequencing tests to expand their panel of targets to include for markers of PRMT5 inhibition."

Mirati Therapeutics Announces Proposed Public Offering

Retrieved on: 
Tuesday, August 8, 2023
Attention, SVB Securities, File, Telephone, Mirati Therapeutics, Goldman Sachs, Sale, Prospectus, SAN, Mirati, Security (finance), Therapy

In addition, Mirati expects to grant the underwriters of the offering a 30-day option to purchase up to an additional $37.5 million of shares at the public offering price, less the underwriting discounts and commissions.

Key Points: 
  • In addition, Mirati expects to grant the underwriters of the offering a 30-day option to purchase up to an additional $37.5 million of shares at the public offering price, less the underwriting discounts and commissions.
  • The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
  • Goldman Sachs & Co. LLC is acting as the book-running manager for the proposed offering.
  • Leerink Partners LLC is acting as financial advisor for the proposed offering.

Mirati Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Updates

Retrieved on: 
Tuesday, August 8, 2023
PDAC, Docetaxel, KRAS, American Journal of Clinical Oncology, Marketing, MTA, Pharming, European Medicines Agency, Cholangiocarcinoma, New Drug Application, American Society of Clinical Oncology, SOS1, Cancer Discovery (journal), SAPPHIRE, Cancer, Clinical trial, Committee on Herbal Medicinal Products, Mirati Therapeutics, NSCLC, Cetuximab, TPS, Trial of the century, Committee, EMA, ASCO, Conditional, Shanda, Journal, Outline, Patient, Investment, Manuscript, Meekness, Colorectal cancer, Committee for Medicinal Products for Human Use, Annual general meeting, MAA, Research, FDA, Pembrolizumab, Therapy, Society, Nivolumab, PRMT5, CHMP, Cryptocurrency, Communications satellite, Pharmaceutical industry, Nursing

SAN DIEGO, Aug. 8, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced financial results for the second quarter 2023 along with recent pipeline and corporate updates.

Key Points: 
  • ET / 2:30 p.m. PT
    SAN DIEGO, Aug. 8, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced financial results for the second quarter 2023 along with recent pipeline and corporate updates.
  • Based on these results, the Company plans to discuss a tumor agnostic Accelerated Approval approach with FDA by year-end 2023.
  • Net reduction in cash, cash equivalents and short-term investments for the second quarter of 2023 was $122.9 million.
  • ET / 2:30 p.m. PT during which company executives will review financial information for the second quarter and provide corporate updates.